Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Baxter
McKesson
AstraZeneca

Last Updated: August 19, 2022

Investigational Drug Information for PF-04958242


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for PF-04958242?

PF-04958242 is an investigational drug.

There have been 14 clinical trials for PF-04958242. The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.

The most common disease conditions in clinical trials are Schizophrenia, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Biogen, Pfizer, and Yale University.

There are forty-three US patents protecting this investigational drug and four hundred and thirteen international patents.

Recent Clinical Trials for PF-04958242
TitleSponsorPhase
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsBiogenPhase 1
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)BiogenPhase 2
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)BiogenPhase 2

See all PF-04958242 clinical trials

Clinical Trial Summary for PF-04958242

Top disease conditions for PF-04958242
Top clinical trial sponsors for PF-04958242

See all PF-04958242 clinical trials

US Patents for PF-04958242

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-04958242 See Plans and Pricing 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides Pfizer Inc. (New York, NY) See Plans and Pricing
PF-04958242 See Plans and Pricing Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors Pfizer Inc. (New York, NY) See Plans and Pricing
PF-04958242 See Plans and Pricing Imidazopyridazine compounds Pfizer Inc. (New York, NY) See Plans and Pricing
PF-04958242 See Plans and Pricing N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides Pfizer Inc. (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-04958242

Drugname Country Document Number Estimated Expiration Related US Patent
PF-04958242 Argentina AR099997 2034-04-10 See Plans and Pricing
PF-04958242 Australia AU2015245260 2034-04-10 See Plans and Pricing
PF-04958242 Canada CA2944971 2034-04-10 See Plans and Pricing
PF-04958242 Chile CL2016002510 2034-04-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Baxter
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.